JJ Bienaimé is moving out of the C-suite after an 18-year run at BioMarin. And you likely know his successor

Feisty, stubborn Jean-Jacques Bienaimé is stepping down from the top post at BioMarin after an 18-year run with a string of highlights in 2023. And he’s handing the reins to his carefully-picked successor: Alexander Hardy, the CEO at industry stalwart Genentech.

The change at the top — as the 70-year-old Bienaimé moves to an advisory role next year after exiting the C-suite Dec. 1 — includes Richard Meier, an independent director who is moving into the role of chair of the board.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Lifera, Sanofi Arabio boost vaccine manufacturing in Saudi Arabia

Ten million people annually receive Sanofi’s vaccines in the Gulf region. Credit: BaLL LunLa via Shutterstock.com. Saudi Arabia-based biopharmaceutical companies Lifera and Arabio and French

July 6, 2023

GSK asks US patent office to refuse Moderna’s ‘Covid Mvax’ trademark registration as ‘too generic’

Before there were Covid-19 vaccines, there were trademarked names for Covid-19 vaccines. The pharma companies working fast and furiously on the scientific discoveries in 2020

August 24, 2023

Opinion | Doing More With Less Blood

Frank is a professor of anesthesiology and critical care medicine. In 1988, I was a third-year anesthesia resident on a casual weekend bike ride with

December 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.